Filing Details
- Accession Number:
- 0001144204-10-047804
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2010-09-01 17:02:03
- Reporting Period:
- 2010-09-01
- Filing Date:
- 2010-09-01
- Accepted Time:
- 2010-09-01 17:02:03
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1095858 | Ivax Diagnostics Inc | IVD | Pharmaceutical Preparations (2834) | 113500746 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1444608 | Umbria Llc | C/O Fiduciaire Jean-Marc Faber 63-65 , Rue De Merl Luxembourg N4 L - 2146 | No | No | Yes | No | |
| 1444812 | F. Paul Kennedy | 81 Bd Suchet Paris I0 75016 | Yes | No | Yes | No | |
| 1444813 | Patrice Debregeas | 79, Rue De Miromesnil Paris I0 75008 | Yes | No | Yes | No | |
| 1444956 | Sas Pharma Associes & Debregeas | 79 Rue De Miromesnil Paris I0 75008 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.01 Par Value | Disposition | 2010-09-01 | 14,350,000 | $0.75 | 0 | No | 4 | S | Direct | |
| Common Stock, $0.01 Par Value | Disposition | 2010-09-01 | 26,313 | $0.75 | 0 | No | 4 | S | Direct | |
| Common Stock, $0.01 Par Value | Disposition | 2010-09-01 | 2,850,000 | $0.75 | 0 | No | 4 | S | Direct | |
| Common Stock, $0.01 Par Value | Disposition | 2010-09-01 | 2,800,000 | $0.75 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- On September 1, 2010, a group comprised of Debregeas & Associes Pharma SAS, Patrice R. Debregeas, Umbria LLC and Paul F. Kennedy sold to ERBA Diagnostics Mannheim GmbH (the "Purchaser"), in a privately negotiated transaction, an aggregate of 20,026,313 shares of the issuer's common stock at a purchase price of $0.75 per share (the "Transaction").
- Represents shares of the issuer's common stock sold in the Transaction which were directly owned solely by Debregeas & Associes Pharma SAS and indirectly owned by Patrice R. Debregeas, who may be deemed to control Debregeas & Associes Pharma SAS.
- Represents shares of the issuer's common stock sold in the Transaction which were directly owned solely by Patrice R. Debregeas.
- Represents shares of the issuer's common stock sold in the Transaction which were directly owned solely by Umbria LLC and indirectly owned by Paul F. Kennedy, the sole equity owner of Umbria LLC.
- Represents shares of the issuer's common stock sold in the Transaction which were directly owned solely by Paul F. Kennedy.
- In connection with the consummation of the Transaction, Patrice R. Debregeas and Paul F. Kennedy resigned as directors of the issuer, effective immediately.
Billionaire Hedge Funds
